#USA #Cortechs.ai #NeuroQuant #AI Imaging #Covington

Cortechs.ai Announces Expansion of CE Marking in Europe

In a significant development for the field of medical imaging, Cortechs.ai, recognized as a leader in AI-driven quantitative imaging solutions, has announced the upward expansion of its European CE marking. This move pertains to several of its cutting-edge imaging products, including the latest Version 5 of NeuroQuant, NeuroQuant Brain Tumor, and OnQ Prostate. These products have all been certified under the stringent European Union Medical Device Regulation (EU MDR).

Meeting Rigorous Standards

The approval signifies that Cortechs.ai's innovative imaging products comply with the EU MDR's demanding standards for safety, performance, and quality. This certification facilitates the commercialization of Cortechs.ai's offerings throughout the vast European Economic Area (EEA), marking a key milestone in the company’s strategy for global expansion across the medical technology sector.

Kyle Frye, the CEO of Cortechs.ai, highlighted the importance of this CE marking, stating, "This achievement is the result of over a year’s commitment from our entire organization. It represents one of the most rigorous regulatory milestones in medical technology. The diverse healthcare environment in Europe presents an opportunity for us to deliver our latest innovations and enhance patient care standards globally."

Enhanced Product Portfolio

Cortechs.ai’s flagship platform, NeuroQuant, specializes in quantifying neurological conditions, automating brain segmentation, and providing comprehensive volumetric analysis. With its updated version, clinicians can efficiently assess and monitor a range of conditions, including Alzheimer's disease and multiple sclerosis, thereby advancing patient diagnostics and treatment strategies.

In addition, the NeuroQuant Brain Tumor platform allows specialists to visualize and conduct longitudinal monitoring of brain tumors, facilitating objective disease progression assessments over time. The OnQ Prostate product, which employs advanced Restriction Spectrum Imaging (RSI), equips clinicians with enhanced capabilities for the detection and evaluation of clinically significant prostate cancer.

This expansion embodies Cortechs.ai's long-term vision of establishing a unified, AI-centric imaging platform that spans the domains of neurology, neuro-oncology, and prostate imaging. An investment in innovation illustrates their commitment to empowering physicians with objective imaging intelligence, which ultimately enhances patient care and outcomes.

Collaborative Efforts Drive Success

Nate White, Cortechs.ai's Chief Technology Officer, emphasized that this accomplishment exemplifies the dedication and teamwork across the company's various departments, including Product, Engineering, Regulatory, Clinical, and Quality teams. He remarked, "Our unwavering commitment to excellence during this process not only enabled us to achieve this important certification but also positions Cortechs.ai for further innovation and expansion."

With the expanded CE certification formally in place, Cortechs.ai is now progressing towards broader European commercialization while simultaneously enhancing additional platform capabilities to maintain its leadership in AI-powered quantitative imaging.

Looking Ahead

Cortechs.ai stands at the forefront of revolutionizing how medical imaging is perceived and utilized in clinical practice. The company's advancements in AI technology not only facilitate earlier disease detection but also enable improved patient outcomes. The recent CE marking expansion reinforces Cortechs.ai’s role as an influential entity in the healthcare landscape, committed to bringing groundbreaking solutions to physicians and their patients worldwide.

For further information about Cortechs.ai and its innovative range of imaging solutions, stakeholders and interested parties can visit their website or follow them on various social media platforms.